Congratulations to our client Chemomab Therapeutics (“Chemomab”) on completing a merger with public company Anchiano Therapeutics. The combined company now goes by Chemomab Therapeutics Ltd. and is traded on Nasdaq under the symbol “CMMB”. Chemomab is an Israeli, clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need.

Acting as U.S. counsel to Chemomab was GT’s legal team led by Bob Grossman, Chair of Greenberg Traurig’s Israel Practice and senior M&A and financing attorney at the firm’s Miami office, together with Drew Altman, Chair of the Miami Corporate Practice with considerable experience in Israeli transactions, with the support from Ephraim Schmeidler, Corporate Tel Aviv attorney.

To read the full press release, click here.